Daiichi-Sankyo's triple antihypertensive launched in the UK
This article was originally published in Scrip
Daiichi-Sankyo has launched its triple antihypertensive product Sevikar HCT in the UK, following its decentralised EU approval last year. The product contains the angiotensin II receptor blocker (ARB) olmesartan medoxomil, the calcium channel blocker amlodipine and the diuretic hydrochlorothiazide, and was first launched in Europe late last year in Germany, following its market debut in the US as Tribenzor.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.